BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/13/2017 7:05:00 PM | Browse: 859 | Download: 1682
 |
Received |
|
2016-12-02 10:29 |
|
Peer-Review Started |
|
2016-12-02 11:09 |
|
To Make the First Decision |
|
2016-12-19 11:10 |
|
Return for Revision |
|
2016-12-23 16:57 |
|
Revised |
|
2017-01-06 19:07 |
|
Second Decision |
|
2017-01-16 11:32 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2017-01-18 11:36 |
|
Articles in Press |
|
2017-01-18 11:36 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2017-02-15 02:34 |
|
Typeset the Manuscript |
|
2017-03-06 10:06 |
|
Publish the Manuscript Online |
|
2017-03-13 19:06 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
|
| Copyright |
© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
|
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Basic Study |
| Article Title |
ECRG2 enhances the anti-cancer effects of cisplatin in cisplatin-resistant esophageal cancer cells via upregulation of p53 and downregulation of PNCA
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Xin-Fang Hou, Lin-Ping Xu, Hai-Yan Song, Shuai Li, Chen Wu and Ju-Feng Wang |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| the Public Welfare Project Foundation of Henan Province |
20130010 |
|
| Corresponding Author |
Dr. Ju-Feng Wang, Professor, Department of Medical Oncology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, 127 Dongming Road, Zhengzhou 450008, Henan Province,
China. 13783583966@163.com
|
| Key Words |
Esophageal cancer related-gene 2; Cisplatin; Resistance; p53; Proliferating cell nuclear antigen |
| Core Tip |
Cisplatin (DDP) is one of the most effective agents in treating esophageal cancer, but drug resistance poses a major impediment. Combination therapy has become an important method for overcoming drug resistance. This study showed that esophageal cancer-related gene 2 (ECRG2) in combination with DDP can inhibit viability and induce apoptosis in DDP-resistant esophageal cancer cells, possibly via upregulation of p53 expression and downregulation of proliferating cell nuclear antigen expression. These findings suggest that the combination of ECRG2 and DDP may be a promising strategy for the clinical treatment of esophageal cancers that are resistant to DDP.
|
| Publish Date |
2017-03-13 19:06 |
| Citation |
Hou XF, Xu LP, Song HY, Li S, Wu C, Wang JF. ECRG2 enhances the anti-cancer effects of cisplatin in cisplatin-resistant esophageal cancer cells via upregulation of p53 and downregulation of PNCA. World J Gastroenterol 2017; 23(10): 1796-1803 |
| URL |
http://www.wjgnet.com/1007-9327/full/v23/i10/1796.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v23.i10.1796 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
